VERO vs SSKN

For growth investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger pick with 0. 6% revenue growth year-over-year, versus -15. 1% for Venus Concept Inc. (VERO). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, STRATA Skin Sciences, Inc.

(SSKN) delivered a total return of -98. 9%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: SSKN returned -99. 6% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 24β versus Venus Concept Inc. 's 1. 43β — meaning VERO is approximately -686% more volatile than SSKN relative to the S&P 500. On balance sheet safety, STRATA Skin Sciences, Inc. (SSKN) carries a lower debt/equity ratio of 3% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), STRATA Skin Sciences, Inc.

(SSKN) is pulling ahead at 0. 6% versus -15. 1% for Venus Concept Inc. (VERO). On earnings-per-share growth, the picture is similar: STRATA Skin Sciences, Inc. grew EPS 16. 1% year-over-year, compared to -869. 0% for Venus Concept Inc.. Over a 3-year CAGR, SSKN leads at 3. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

STRATA Skin Sciences, Inc.

(SSKN) is the more profitable company, earning -30. 1% net margin versus -72. 5% for Venus Concept Inc. — meaning it keeps -30. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SSKN leads at -27. 6% versus -41. 9% for VERO. At the gross margin level — before operating expenses — VERO leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). Both have compounded well over 10 years (SSKN: -99. 6%, VERO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.